TELA (TELA Bio) Current Deferred Revenue: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TELA TELA Bio Inc TELA
50 GF Score
Price $0.70
GF Value $1.43
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is TELA Bio Current Deferred Revenue?

TELA Bio TELA +7.03% 50 Current Deferred Revenue is $0.00 Mil as of Jun. 2026. GuruFocus rates TELA with a GF Score™ of 50/100 and a GF Value™ of $1.43 (Possible Value Trap). The stock has 5 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

TELA Bio's current deferred revenue for the quarter that ended in Jun. 2026 was $0.00 Mil.

TELA Bio Current Deferred Revenue Related Terms

TELA Bio Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for TELA Bio's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TELA Bio Current Deferred Revenue Chart

TELA Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

TELA Bio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TELA
50GF Score
TELA Bio Inc TELA
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $0.00 Mil mean?
TELA Bio (TELA) has a Current Deferred Revenue of $0.00 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on TELA Bio and its competitors.
Is TELA Bio's Current Deferred Revenue too high?
TELA Bio's current Current Deferred Revenue is $0.00 Mil. Overall, TELA Bio has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TELA Bio's Current Deferred Revenue compare to NSPR and RDGL?
TELA Bio's Current Deferred Revenue of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Devices & Instruments company?
A good Current Deferred Revenue depends on the Medical Devices & Instruments industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on TELA Bio and its competitors. TELA Bio's current Current Deferred Revenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TELA Bio stock overvalued right now?
Based on GuruFocus' analysis, TELA Bio (TELA) is currently considered Possible Value Trap. The stock's GF Value™ is $1.43, compared to a current price of $0.70 — trading 51% below its estimated fair value. The current Current Deferred Revenue is $0.00 Mil. TELA Bio's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For TELA Bio (TELA), the current Current Deferred Revenue is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TELA Bio (TELA) Overvalued in 2026?

Based on GuruFocus' analysis, TELA Bio stock appears to be undervalued. The current stock price of $0.70 is trading 51% below its estimated GF Value™ of $1.43. GuruFocus considers TELA Bio to be Possible Value Trap.

Key valuation signals for TELA:

  • Current Deferred Revenue: $0.00 Mil
  • GF Value™: $1.43 vs. price of $0.70 (51% below fair value)
  • GF Score™: 50/100 with 5 warning signs

No single metric tells the full story. See the TELA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TELA Bio Business Description

Address 1 Great Valley Parkway, Suite 24, Malvern, PA, USA, 19355
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
50GF Score

Get the complete analysis for TELA

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.70
Price
$1.43
GF Value